Guy Chouinard

Guy Chouinard's AcademicInfluence.com Rankings

Guy Chouinard

Biology

#9510

World Rank

#12725

Historical Rank

biology Degrees

Download Badge

Biology

Guy Chouinard's Degrees

PhD Psychiatry McGill University
Doctorate Medicine McGill University

Why Is Guy Chouinard Influential?

(Suggest an Edit or Addition)

(See a Problem?)

Guy Chouinard's Published Works

Number of citations in a given year to any of this author's works

Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author

Published Works

Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). (2003) (1196)
A Canadian multicenter placebo-controlled study of fixed doses of risperidone and haloperidol in the treatment of chronic schizophrenic patients. (1993) (827)
The effects of risperidone on the five dimensions of schizophrenia derived by factor analysis: combined results of the North American trials. (1997) (668)
Manual for the Extrapyramidal Symptom Rating Scale (ESRS) (2005) (367)
Elevated dopa decarboxylase activity in living brain of patients with psychosis. (1994) (343)
Issues in the clinical use of benzodiazepines: potency, withdrawal, and rebound. (2004) (283)
Neuroleptic-induced supersensitivity psychosis: clinical and pharmacologic characteristics. (1980) (281)
Antidepressant efficacy of sertraline: a double-blind, placebo- and amitriptyline-controlled, multicenter comparison study in outpatients with major depression. (1990) (261)
Placebo-controlled study of gabapentin treatment of panic disorder. (2000) (259)
Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. (1995) (225)
Neuroleptic-induced supersensitivity psychosis. (1978) (207)
Risperidone in the Treatment of Tourette Syndrome: A Double-Blind, Placebo-Controlled Trial (2002) (182)
Antipsychotic-Induced Dopamine Supersensitivity Psychosis: Pharmacology, Criteria, and Therapy (2017) (165)
A comparison of venlafaxine, trazodone, and placebo in major depression. (1994) (157)
Results of a double-blind placebo controlled trial of a new serotonin uptake inhibitor, sertraline, in the treatment of obsessive-compulsive disorder. (1990) (148)
Atypical Antipsychotics: CATIE Study, Drug-Induced Movement Disorder and Resulting Iatrogenic Psychiatric-Like Symptoms, Supersensitivity Rebound Psychosis and Withdrawal Discontinuation Syndromes (2008) (145)
Reduction of hospital days in chronic schizophrenic patients treated with risperidone: a retrospective study. (1993) (143)
Response to steroid suppression in major depression resistant to antidepressant therapy. (1991) (138)
Antimanic effect of clonazepam. (1983) (136)
Treatment of schizophrenia 1999 (1999) (136)
Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment. (1984) (135)
Tardive Dyskinesia in the Era of Typical and Atypical Antipsychotics. Part 1: Pathophysiology and Mechanisms of Induction (2005) (128)
Extended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled study. (2010) (127)
Factors related to tardive dyskinesia. (1979) (125)
Effects of Risperidone in Tardive Dyskinesia: An Analysis of the Canadian Multicenter Risperidone Study* (1995) (125)
New Classification of Selective Serotonin Reuptake Inhibitor Withdrawal (2015) (123)
A 1 year double‐blind placebo‐controlled fixed dose study of sertraline in the treatment of obsessive‐compulsive disorder (1995) (123)
Loss of striatal cholinergic neurons as a basis for tardive and L-dopa-induced dyskinesias, neuroleptic-induced supersensitivity psychosis and refractory schizophrenia (1993) (122)
Tardive Dyskinesia in the Era of Typical and Atypical Antipsychotics. Part 2: Incidence and Management Strategies in Patients with Schizophrenia (2005) (119)
Gabapentin: long-term antianxiety and hypnotic effects in psychiatric patients with comorbid anxiety-related disorders. (1998) (118)
Severe cases of neuroleptic-induced supersensitivity psychosis Diagnostic criteria for the disorder and its treatment (1991) (117)
A 5-year prospective longitudinal study of tardive dyskinesia: factors predicting appearance of new cases. (1988) (116)
Economic and health state utility determinations for schizophrenic patients treated with risperidone or haloperidol. (1997) (105)
Acute and Persistent Withdrawal Syndromes Following Discontinuation of Psychotropic Medications (2020) (100)
A review of compliance, depot intramuscular antipsychotics and the new long-acting injectable atypical antipsychotic risperidone in schizophrenia (2004) (98)
Abnormal Involuntary Movement Scale (AIMS) and Extrapyramidal Symptom Rating Scale (ESRS): Cross-scale comparison in assessing tardive dyskinesia (2005) (96)
Guidelines for the clinical use of benzodiazepines: pharmacokinetics, dependency, rebound and withdrawal. Canadian Society for Clinical Pharmacology. (1999) (95)
A double-blind randomized clinical trial of rapid tranquilization with I.M. clonazepam and I.M. haloperidol in agitated psychotic patients with manic symptoms. (1993) (82)
Dopamine D4 receptor variant, D4GLYCINE194, in Africans, but not in Caucasians: no association with schizophrenia. (1994) (76)
The psychotropic effects of inhibitors of steroid biosynthesis in depressed patients refractory to treatment (1995) (76)
Drs. Chouinard and Jones Reply (1980) (73)
An open clinical trial of fluoxetine in the treatment of obsessive-compulsive disorder. (1986) (73)
A path-analytical approach to differentiate between direct and indirect drug effects on negative symptoms in schizophrenic patients (1995) (73)
Clinical review of risperidone. (1993) (71)
Double-blind, placebo-controlled study with reboxetine in inpatients with severe major depressive disorder. (2000) (68)
A Canadian multicenter, double-blind study of paroxetine and fluoxetine in major depressive disorder. (1999) (67)
A pilot study of magnesium aspartate hydrochloride (Magnesiocard®) as a mood stabilizer for rapid cycling bipolar affective disorder patients (1990) (64)
Tryptophan‐nicotinamide, imipramine and their combination in depression (1979) (62)
SCHIZOPHRENIA AS DOPAMINE-DEFICIENCY DISEASE (1978) (62)
Metabolism of Anxiolytics and Hypnotics: Benzodiazepines, Buspirone, Zoplicone, and Zolpidem (1999) (61)
Alprazolam in the treatment of generalized anxiety and panic disorders: A double-blind placebo-controlled study (2004) (59)
Topiramate produced weight loss following olanzapine-induced weight gain in schizophrenia. (2002) (58)
Therapeutic Tolerance and Rebound Psychosis During Quetiapine Maintenance Monotherapy in Patients With Schizophrenia and Schizoaffective Disorder (2002) (58)
Treatment of recurrent unipolar major depression with captopril (1988) (58)
The search for new off-label indications for antidepressant, antianxiety, antipsychotic and anticonvulsant drugs. (2006) (56)
Sertraline in the Treatment of Obsessive Compulsive Disorder: Two Double‐blind, Placebo‐controlled Studies (1992) (56)
Fluoxetine in the Long-Term Maintenance Treatment of Obsessive Compulsive Disorder (1989) (54)
ETHOPROPAZINE VS BENZTROPINE IN NEUROLEPTIC-INDUCED PARKINSONISM (1979) (53)
A double-blind controlled clinical trial of fluoxetine and amitriptyline in the treatment of outpatients with major depressive disorder. (1985) (50)
Is DSM-IV bereavement exclusion for major depressive episode relevant to severity and pattern of symptoms? A case-control, cross-sectional study. (2009) (50)
A case of Parkinson's disease exacerbated by fluoxetine (1992) (50)
Intramuscular Olanzapine and Intramuscular Haloperidol in Acute Schizophrenia: Antipsychotic Efficacy and Extrapyramidal Safety during the First 24 Hours of Treatment (2003) (49)
Factors associated with overweight and obesity in schizophrenia, schizoaffective and bipolar disorders (2016) (48)
Clonazepam in the treatment of panic disorder: a double-blind, placebo-controlled trial investigating the correlation between clonazepam concentrations in plasma and clinical response. (1994) (48)
Captopril treatment of major depression with serial measurements of blood cortisol concentrations (1989) (48)
A five year follow-up study of tardive dyskinesia. (1986) (48)
Hypnotics and Triazolobenzodiazepines - Best Predictors of High-Dose Benzodiazepine Use: Results from the Luxembourg National Health Insurance Registry (2015) (47)
A controlled clinical trial of l-tryptophan in acute mania (1985) (47)
New nomenclature for drug-induced movement disorders including tardive dyskinesia. (2004) (46)
Clonazepam in the treatment of patients with recurrent panic attacks. (1986) (46)
Phase-IV Multicentre Clinical Study of Risperidone in the Treatment of Outpatients with Schizophrenia (1998) (45)
A controlled dose‐ranging study of remoxipride and haloperidol in schizophrenia ‐ a Canadian multicentre trial (1990) (45)
Supersensitivity psychosis and tardive dyskinesia: a survey in schizophrenic outpatients. (1986) (45)
The need for a behavioural science focus in research on mental health and mental disorders (2014) (44)
A cross-sectional study of parkinsonism and tardive dyskinesia in lithium-treated affective disordered patients. (1996) (44)
An open clinical trial of zimeldine in the treatment of obsessive compulsive disorder (1985) (43)
New concepts in benzodiazepine therapy: Rebound anxiety and new indications for the more potent benzodiazepines (1983) (41)
Tardive dyskinesia and antiparkinsonian medication. (1979) (40)
Olanzapine-induced somnambulism. (2001) (40)
Clonazepam in acute and maintenance treatment of bipolar affective disorder. (1987) (40)
Midazolam: kinetics and effects on memory, sensorium, and haemodynamics. (1987) (38)
Risperidone and clozapine in the treatment of drug-resistant schizophrenia and neuroleptic-induced supersensitivity psychosis (1994) (38)
A double-blind, placebo-controlled study of piracetam in elderly psychiatric patients [proceedings]. (1981) (38)
Patient Online Report of Selective Serotonin Reuptake Inhibitor-Induced Persistent Postwithdrawal Anxiety and Mood Disorders (2012) (38)
Brain bioenergetics and redox state measured by 31P magnetic resonance spectroscopy in unaffected siblings of patients with psychotic disorders (2017) (37)
Zopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxiety. (1990) (37)
An early phase II clinical trial of tomoxetine (LY139603) in the treatment of newly admitted depressed patients (2004) (36)
A comparative study of bupropion and amitriptyline in depressed outpatients. (1983) (36)
A placebo‐controlled clinical trial of remoxipride and chlorpromazine in newly admitted schizophrenic patients with acute exacerbation (1990) (36)
Estrogen-progesterone combination: another mood stabilizer? (1987) (35)
The international suicide prevention trial (interSePT): rationale and design of a trial comparing the relative ability of clozapine and olanzapine to reduce suicidal behavior in schizophrenia and schizoaffective patients. (2004) (35)
Fluoxetine in the treatment of obsessive compulsive disorder (1985) (35)
Schizophreniform psychosis associated with chronic industrial toluene exposure: case report. (1985) (34)
Persistent Postwithdrawal Disorders Induced by Paroxetine, a Selective Serotonin Reuptake Inhibitor, and Treated with Specific Cognitive Behavioral Therapy (2014) (34)
Clozapine in the Treatment of Newly Admitted Schizophrenic Patients A Pilot Study (1976) (34)
Antimanic effects of clonazepam. (1985) (33)
Potentiation of lithium by tryptophan in a patient with bipolar illness. (1979) (32)
Antipanic effect of clonazepam. (1984) (32)
Bupropion and amitriptyline in the treatment of depressed patients. (1983) (31)
Clonazepam in the treatment of neuroleptic-induced somnambulism. (2006) (31)
Interaction between caffeine and clozapine. (1994) (30)
Gabapentin in the treatment of antipsychotic-induced akathisia in schizophrenia. (2005) (30)
Fast-cycling bipolar disorder induced by withdrawal from long-term treatment with a tricyclic antidepressant. (1984) (29)
Olanzapine-induced neuroleptic malignant syndrome with mental retardation. (1999) (29)
A case of mania associated with tomoxetine. (1985) (29)
The use of benzodiazepines in the treatment of manic-depressive illness. (1988) (29)
Persistent tardive rebound panic disorder, rebound anxiety and insomnia following paroxetine withdrawal: a review of rebound-withdrawal phenomena. (2006) (28)
A randomized clinical trial of haloperidol decanoate and fluphenazine decanoate in the outpatient treatment of schizophrenia. (1989) (28)
A Rating Scale for Psychotic Symptoms (RSPS) Part I: theoretical principles and subscale 1: perception symptoms (illusions and hallucinations) (1999) (28)
Withdrawal and rebound symptoms associated with abrupt discontinuation of venlafaxine. (1998) (27)
Amitriptyline-perphenazine interaction in ambulatory schizophrenic patients. A controled study of drug interaction. (1975) (27)
Tryptophan dosage critical for its antidepressant effect. (1978) (27)
Fluphenazine enanthate and fluphenazine decanoate in the treatment of schizophrenic outpatients: extrapyramidal symptoms and therapeutic effect. (1982) (27)
A case of mania induced by high-dose fluoxetine treatment. (1986) (27)
Topiramate-induced weight loss in schizophrenia: a retrospective case series study. (2007) (27)
International Task Force on Benzodiazepines (2018) (26)
Clinical guidelines on antidepressant withdrawal urgently need updating (2019) (26)
Bromazepam and lorazepam in generalized anxiety: a placebo‐controlled study with measurement of drug plasma concentrations (1986) (26)
A controlled clinical trial of fluspirilene, a long-acting injectable neuroleptic, in schizophrenic patients with acute exacerbation. (1986) (26)
TRYPTOPHAN-NICOTINAMIDE COMBINATION IN DEPRESSION (1977) (25)
Comparison of withdrawal of buspirone and diazepam: A placebo controlled study (1987) (25)
A Guide to Benzodiazepine Selection. Part II: Clinical Aspects (1991) (24)
Cutaneous vasculitis induced by paroxetine. (2001) (24)
Emerging clinical trends and perspectives on comorbid patterns of mental disorders in research (2014) (24)
Psychosis associated with elevated trough tacrolimus blood concentrations after combined kidney-pancreas transplant. (2006) (24)
Didanosine-induced mania in HIV infection. (1994) (23)
A Guide to Benzodiazepine Selection. Part I: Pharmacological Aspects* (1990) (23)
Neuroleptic‐induced supersensitivity psychosis in patients with bipolar affective disorder (1990) (23)
Evidence of Brain Dopamine Deficiency in Schizophrenia (1979) (23)
Dysphoric mania induced by high-dose mirtazapine: a case for 'norepinephrine syndrome'? (2002) (22)
Withdrawal symptoms after long-term treatment with low-potency neuroleptics. (1984) (22)
Moclobemide Update of its Pharmacological Properties and Therapeutic Use (1996) (22)
Risperidone-induced morning pseudoneutropenia. (2005) (21)
Pimozide in the treatment of chronic schizophrenic patients. (1970) (20)
Antiobsessive effect of fluoxetine. (1985) (20)
Early phase II clinical trial of remoxipride in treatment of schizophrenia with measurements of prolactin and neuroleptic activity. (1987) (20)
Hypomania induced by sertraline, a new serotonin reuptake inhibitor. (1987) (20)
Cognitive Impairment in Systemic Lupus Erythematosus Women with Elevated Autoantibodies and Normal Single Photon Emission Computerized Tomography (2012) (19)
Piracetam in elderly psychiatric patients with mild diffuse cerebral impairment (2004) (19)
Clonazepam in the treatment of recurrent symptoms of depression and anxiety in a patient with systemic lupus erythematosus. (1985) (19)
Differences in psychopathology of schizophrenic patients with normal and abnormal postimperative negative variation (PINV). (1977) (19)
Early onset of tardive dyskinesia: case report. (1979) (19)
Rebound anxiety in anxious patients after abrupt withdrawal of benzodiazepine treatment (1984) (19)
Late-onset agranulocytosis in a patient with schizophrenia after 17 months of clozapine treatment. (2003) (18)
Death attributed to ventricular arrhythmia induced by thioridazine in combination with a single Contac C capsule. (1978) (18)
A Canadian multicentre placebo-controlled study of a fixed dose of brofaromine, a reversible selective MAO-A inhibitor, in the treatment of major depression. (1994) (18)
Moclobemide versus fluoxetine in the treatment of major depressive disorder in adults. (1997) (18)
Pimozide in the treatment of newly admitted schizophrenic patients (2004) (18)
Treatment of supersensitivity psychosis with antiepileptic drugs: report of a series of 43 cases. (1990) (17)
Interrelations between psychiatric symptoms and drug-induced movement disorder. (2006) (17)
Penfluridol in the treatment of newly admitted schizophrenic patients in a brief therapy unit. (1976) (17)
Gabapentin-Induced Paradoxical Exacerbation of Psychosis in a Patient with Schizophrenia (2002) (17)
The Prescription of Benzodiazepines for Panic Disorder: Time for an Evidence-Based Educational Approach. (2018) (17)
Lack of tolerance to long‐term neuroleptic treatment in dopamine tuberoinfundibular system (1981) (17)
Long-term effects of L-dopa and procyclidine on neuroleptic-induced extrapyramidal and schizophrenic symptoms. (1987) (17)
Bromazepam, another high-potency benzodiazepine, for panic attacks. (1984) (16)
Efficacy and withdrawal of two potent benzodiazepines: bromazepam and lorazepam. (1985) (16)
Successful initiation of clozapine treatment despite morning pseudoneutropenia. (2006) (16)
Serotonin syndrome from addition of low-dose trazodone to nefazodone. (2000) (16)
Risperidone-induced immunoallergic hepatitis. (2005) (15)
The Diagnostic clinical Interview for Drug Withdrawal 1 (DID-W1) – New Symptoms of Selective Serotonin Reuptake Inhibitors (SSRI) or Serotonin Norepinephrine Reuptake Inhibitors (SNRI): inter-rater reliability (2018) (15)
A double-blind, controlled clinical trial of haloperidol decanoate and fluphenazine decanoate in the maintenance treatment of schizophrenia. (1984) (15)
Hypomania induced by adjunctive lamotrigine. (2003) (15)
High neuroleptic plasma levels in patients manifesting supersensitivity psychosis. (1982) (15)
A Rating Scale for Psychotic Symptoms (RSPS): Part II: Subscale 2: distraction symptoms (catatonia and passivity experiences); Subscale 3: delusions and semi-structured interview (SSCI-RSPS) (1999) (14)
Seizures, Coma, and Coagulopathy following Olanzapine Overdose (2005) (14)
A Double‐Blind Comparison of Sertraline and Imipramine in Outpatients with Major Depression: Acute (8 Weeks) and Continuation (16 Weeks) Treatment (1997) (14)
Fluspirilene in the treatment of chronic schizophrenic patients. (1970) (14)
Tardive dyskinesia in a nonpsychiatric patient due to short-term use of a neuroleptic/anticholinergic combination drug. (1982) (14)
Diabetes, Tardive Dyskinesia, Parkinsonism, and Akathisia in Schizophrenia: A Retrospective Study Applying 1998 Diabetes Health Care Guidelines to Antipsychotic Use (2004) (14)
Long-Term Lamotrigine Adjunctive to Antipsychotic Monotherapy in Schizophrenia: Further Evidence (2004) (14)
Postimperative negative variation (PINV) in ambulatory schizophrenic patients. (1975) (14)
A Double‐Blind Controlled Study of Pipothiazine Palmitate in the Maintenance Treatment of Schizophrenic Outpatients (1978) (13)
Non-response to consecutive antidepressant therapy caused by CYP2D6 ultrarapid metabolizer phenotype. (2008) (13)
Diphenhydramine (Unisom), a central anticholinergic and antihistaminic: abuse with massive ingestion in a patient with schizophrenia. (2000) (13)
Rebound cardiac arrhythmia after withdrawal from imipramine: a case report. (1981) (12)
An early Phase II clinical trial with followup of tomoxetine (LY139603) in the treatment of newly admitted depressed patients. (1985) (12)
The Monoamine Hypothesis of Depression Revisited: Could It Mechanistically Novel Antidepressant Strategies? (2019) (12)
Obsessive—Compulsive Symptoms in Schizophrenia Induced by Risperidone and Responding to Fluoxetine (2003) (11)
Potentiation of fluoxetine by aminoglutethimide, an adrenal steroid suppressant. in obsessive-compulsive disorder resistant to ssris: A case report (1996) (11)
ECT in delusional depression with multiple sclerosis. (2004) (11)
Antiepileptic drugs in the treatment of neuroleptic-induced supersensitivity psychosis (1990) (11)
Potentiation of haloperidol by -methyldopa in the treatment of schizophrenic patients. (1973) (11)
Bromazepam and diazepam in generalized anxiety: a placebo-controlled study of efficacy and withdrawal. (1984) (11)
Alpha methyldopa-chlorpromazine interaction in schizophrenic patients. (1973) (11)
Cocaine Use Disorder Treated with Specific Cognitive Behavioral Therapy and Adjunctive Propranolol (2015) (11)
Normal and Pathological Aging of Attention in Presymptomatic Huntington’s, Huntington’s and Alzheimer’s Disease, and Nondemented Elderly Subjects (2008) (11)
Does a long-acting atypical antipsychotic offer a low risk of tardive dyskinesia in patients with schizophrenia? (2003) (11)
An early phase II clinical trial of remoxipride in schizophrenia with measurement of plasma neuroleptic activity. (1986) (11)
The effect of rubidium in schizophrenia. (1977) (10)
Plasma levels of neuroleptic in patients receiving depot fluphenazine. (1985) (10)
No crossover of hypersensitivity between zimelidine and fluoxetine. (1984) (10)
Type I tardive dyskinesia induced by anticholinergic drugs, dopamine agonists and neuroleptics (1982) (10)
Antiparkinsonian drug administration and plasma levels of penfluridol, a new long-acting neuroleptic. (1977) (10)
Phenothiazine-induced ECG abnormalities: effect of a glucose load. (1977) (9)
An early Phase II clinical trial of BW234U in the treatment of acute schizophrenia in newly admitted patients (2004) (9)
An open clinical trial of clonazepam in the treatment of patients with recurrent panic attacks (1985) (9)
Reversible and irreversible tardive dyskinesia: a case report. (1982) (9)
Clozapine for first-episode schizophrenia. (2002) (9)
Tryptophan in the treatment of depression. (1981) (8)
Penfluridol in the Maintenance Treatment of Schizophrenic Patients Newly Discharged from A Brief Therapy Unit (1977) (8)
Tryptophan-nicotinamide combination in the treatment of newly admitted depressed patients. (1978) (8)
Sex differences and tardive dyskineasia. (1980) (8)
New Clinical Concepts on Neuroleptic-Induced Supersensitivity Disorders: Tardive Dyskinesia and Supersensitivity Psychosis (1984) (8)
Determination of plasma bupropion and its relationship to therapeutic effect. (1984) (8)
Meta-analytic study of the benefits and risks of treating chronic schizophrenia with risperidone or conventional neuroleptics (1998) (7)
Beyond DSM-IV Bereavement Exclusion Criterion E for Major Depressive Disorder (2010) (7)
Ineffectiveness of deanol in tardive dyskinesia: A placebo controlled study (2004) (7)
Absence of orthostatic hypotension in depressed patients treated with bupropion. (1981) (7)
ANTIDYSKINETIC EFFECT OF RISPERIDONE IN CHRONIC SCHIZOPHRENIC PATIENTS (1992) (7)
Erratum to “Manual for the Extrapyramidal Symptom Rating Scale (ESRS)” [Schizophrenia Research 76 (2–3) (2005) 247–265] (2006) (6)
65-77 The clinical actions of risperidone (1997) (6)
Remoxipride in the treatment of acute mania (1986) (6)
Remoxipride in schizophrenia: Effects on plasma prolactin (1985) (6)
Manic-depressive illness associated with Klinefelter's syndrome and essential tremors. (1978) (6)
A controlled study of a dopa decarboxylase inhibitor (benserazide) in the treatment of schizophrenic patients. (1977) (6)
Additional comments on benzodiazepine withdrawal (1988) (6)
Brofaromine in depression: a Canadian multicenter placebo trial and a review of standard drug comparative studies. (1993) (6)
The Therapeutic Action of Tryptophan in Depression, Mania, and Aggression (1984) (5)
Loxapine succinate in the treatment of newly admitted schizophrenic patients. (1977) (5)
Factors affecting the course of tardive dyskinesia: A ten year follow up study (1989) (5)
Technique for Injecting Long-Acting Neuroleptics (1982) (5)
α-Methyldopa—Chlorpromazine Combination in Schizophrenic Patients (1976) (5)
Poorly Controlled Eps: Risk Factors for NMS (1987) (5)
FACTOR ANALYSIS OF THE EXTRAPYRAMIDAL SYMPTOM RATING SCALE (1992) (4)
Nine-year prophylactic maintenance electroconvulsive therapy in an 89-year-old woman with recurrent psychotic major depressive disorder. (2007) (4)
Benzodiazepines: An update on their mechanisms of action (1996) (4)
Lormetazepam in oral solution: a formulation at risk of high-dose use (2019) (4)
Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry (2022) (4)
Beneficial effects of combined L-dopa and central anticholinergic in a patient with severe drug-induced parkinsonism and tardive dystonia. (1998) (4)
[Iatrogenic psychiatric-like symptoms recognition]. (2010) (4)
Alpha-methyldopa-chlorpromazine combination in schizophrenic patients. (1976) (4)
Reply to Drs. Musser and Kirisci (1995) (4)
Long-term safety and efficacy of tezepelumab in people with severe, uncontrolled asthma (DESTINATION): a randomised, placebo-controlled extension study. (2023) (4)
P0067 - Once-daily extended-release Quetiapine Fumarate (Quetiapine XR) monotherapy in generalised anxiety disorder (GAD): A placebo-controlled study with active-comparator Patoxetine (2008) (3)
Fluoxetine and Preoccupation With Suicide (1991) (3)
FLUOXETINE AND PREOCCUPATION WITH SUICIDE. REPLY (1991) (3)
Long-term sertraline treatment of obsessive compulsive disorder: a 52-week double-blind comparative study versus placebo (1992) (3)
Book Review: Book-Review: Haloperidol Update: 1958–1980. (1981) (2)
Death attributed to ventricular arrhythmia. (1979) (2)
Chlorpromazine-induced electrocardiogram abnormalities. (1975) (2)
CGP 25454A, a novel and selective presynaptic dopamine autoreceptor antagonist (1994) (2)
Clinical Utility of Semistructured Interview and Scales to Assess Withdrawal Syndromes With Dose Reduction or Discontinuation of Selective Serotonin Reuptake Inhibitors or Serotonin Norepinephrine Reuptake Inhibitors (2021) (2)
The new selective dopamine D2 antagonist, remoxipride, in the treatment of acute schizophrenia: A Canadian multicenter trial (1991) (2)
Elevated caudate DOPA decarboxylase activity in vivo in schizophrenia and temporal lobe epilepsy with psychosis (1991) (2)
Dr Corruble and Colleagues Reply (2010) (2)
Clonazepam in treatment of bipolar psychotic patients after discontinuation of neuroleptics. (1989) (2)
Remoxipride — A selective dopamine D2 antagonist in the treatment of acute schizophrenia: a Canadian multicentre clinical trial (1990) (2)
Using the Rating Scale for Psychotic Symptoms to Characterize Delusions Expressed in a Schizophrenia Patient with “Internet Psychosis” (2002) (2)
Aripiprazole Combined with Lamotrigine in the Treatment of a Treatment-Resistant Schizophrenic Patient with Tardive Dyskinesia and Supersensitivity Psychosis (2019) (2)
[The anti-koro effect of a tricyclic antidepressant]. (1990) (2)
Lithium and regression of oat-cell carcinoma. (1981) (2)
Regional Considerations in the Use of Antipsychotic Drugs (1993) (1)
Plasma concentration of neuroleptic and serum prolactin in patients chronically receiving depot fluphenazine: No evidence of tolerance (1987) (1)
[Electroconvulsive therapy in the treatment of depression]. (1977) (1)
Current concepts in schizophrenia: international symposia report new standards for assessment and treatment. Part I: Pathophysiology research prompts assessment updates. (1995) (1)
Endogenous Attention in Normal Elderly, Presymptomatic Huntington’s Disease and Huntington’s Disease Subjects (2012) (1)
Using striatal dopamine transporter single photon emission computed tomography imaging to rule out Dementia with Lewy Bodies in elderly patients with antipsychotic‐induced parkinsonism (2007) (1)
Anticoagulant Selection in Relation to SAMe-TT2R2 Score in Patients with Atrial Fibrillation: The GLORIA-AF Registry. (2020) (1)
The effect of carbidopa and benserazide on human plasma 5-hydroxytryptophan levels (2005) (1)
497 Brain dopa-decarboxylase (DDC) activity in unmedicated schizophrenic patients (1997) (1)
Psychotropic effects of steroid synthesis inhibitors in refractory depression (1994) (1)
Persistent Postwithdrawal Syndrome after Benzodiazepine Discontinuation. A Reply to Huff (2021) (1)
Selective dopamine D2 antagonist, remoxipride,in the treatment of acute schizophrenia - results of proclactin studies (1990) (1)
Included Studies (n = 120) (0)
Theoretical Basis for Response to Steroid Suppression in Major Depression (1992) (0)
Risperidone-induced immunoallergic hepatitis. Author's reply (2005) (0)
O-11-2 Neuroleptic-induced extrapyramidal symptoms: Factor structure (1996) (0)
Letter: Fluphenazine with other antipsychotic drugs. (1975) (0)
A double-blind, multicentre, placebo-controlled study of sertraline in obsessive-compulsive disorder (1991) (0)
[Practical guide for the use of psychopharmaceutic agents. III. Antidepressive agents]. (1977) (0)
Drs. Lesage and Chouinard Reply (1979) (0)
The atypical neuroleptic, remoxipride, and prolactin response in the treatment of acute schizophrenia (1991) (0)
[Further considerations on the use of lithium carbonate and the renal and thyroid disorders resulting from it]. (1980) (0)
[Lithium: third revolution in the history of psychiatric diseases]. (1984) (0)
Book Review: Biological Foundations of Psychiatry, Volumes 1 & 2 (1978) (0)
Economic grand rounds: direct cost of care for patients with schizophrenia treated with haloperidol in an emergency unit. (1999) (0)
Rating Scale for Extrapyramidal Symptoms (2013) (0)
Contents Vol. 81, 2012 (2012) (0)
P.2.f.004 Quantitative EEG cordance, a new predictor of antidepressant response to agomelatine? (2013) (0)
IFP Research Awards: Call for Nominations - Mid-Career Research Award (2015) (0)
[A practical guide for the use of psychopharmacologic agents. II. Antipsychotic and antiparkinson agents]. (1976) (0)
Safety and Efficacy of High-Dose Droperidol in Agitated Patients (1992) (0)
[Schizophrenia and catecholamines]. (1975) (0)
Book Review: Annales de Thérapeutique Psychiatrique (1979) (0)
Correction to: Comparative effectiveness and safety of non-vitamin K antagonists for atrial fibrillation in clinical practice: GLORIA-AF Registry (2022) (0)
[Practical guide for the use of psychopharmacologic agents. I. Use of lithium carbonate]. (1976) (0)
[Factor connected with tardive dyskinesia]. (1979) (0)
When Withdrawal Symptoms Change the Meaning of Research Data (2022) (0)
Therapeutic tolerance to quetiapine: Response to Drs. Goldstein and Macfadden (2004) (0)
Prescription patterns in hospitalized patients with refractory psychoses (1994) (0)
Chronic Airways Assessment Test: psychometric properties in patients with asthma and/or COPD (2023) (0)
Open-label study of captopril in the treatment of major unipolar recurrent depression (1989) (0)
23rd World Congress on Psychosomatic Medicine, Glasgow, 2015 (2014) (0)
Clinical Psychiatry in Primary Care (1982) (0)
Dr. Chouinard Replies (1976) (0)
P.2.117 The clinical actions of risperidone (1997) (0)
Factors Predicting Appearance of New Cases (2011) (0)
Report of the 23rd World Congress on Psychosomatic Medicine, Glasgow, UK, 2015 (2015) (0)
Letters to the EditorThe Author Replies (1988) (0)
Concomitant use of antipsychotics with risperidone. (1996) (0)
[Study of the hypnotic properties of a new benzodiazepine, Mogadon. 2. Comparative evaluation]. (1966) (0)
The psychosis rating scale (PRS): A new scale for positive symptoms of psychosis derived from neurodynamic theory (1998) (0)
Normal and pathological aging of attention in huntington's disease and normal elderly subjects (2007) (0)
Milnacipranof its Use in Depression (1998) (0)
Antidepressant efficacy of sertraline a double blind placebo controlled and amitriptyline controlled multicenter comparison study in outpatients with major depression (1990) (0)
2100 – PROLACTIN LEVELS IN SCHIZOPHRENIC PATIENTS TREATED WITH CHLORPROMAZINE OR TRYPTOPHAN-BENSERAZIDE (1978) (0)

This paper list is powered by the following services:

What Schools Are Affiliated With Guy Chouinard?

Guy Chouinard is affiliated with the following schools:

McGill University